Who is sponsoring SAHRANG?

SAHRANG is sponsored by The University of Texas Health Science Center, Houston.

What condition does SAHRANG study?

SAHRANG studies Subarachnoid Hemorrhage.

What drugs are being tested in SAHRANG?

Interventions: Placebo, 8mg galantamine twice daily, 12mg galantamine twice daily.

What is the status of SAHRANG?

SAHRANG is currently COMPLETED.

Last reviewed 2021-09-10 · How we verify

A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage (SAHRANG)

NCT02872857 Phase 1/Phase 2 COMPLETED Results posted

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

Details

Lead sponsor	The University of Texas Health Science Center, Houston
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	60
Start date	2016-09
Completion	2019-07-20

Conditions

Subarachnoid Hemorrhage

Interventions

Placebo
8mg galantamine twice daily
12mg galantamine twice daily

Primary outcomes

Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug — 90 days
Mortality — 90 days
Modified Rankin Score — 90 days
The Modified Rankin Score (mRS) is scored as follows: 0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead.

Countries

United States